- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05508373
A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Fully Human Anti-CD39 Monoclonal Antibody JS019 in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
Monotherapy Dose Escalation Stage:
In this stage, the safety and tolerability, PK characteristics, immunogenicity and pharmacodynamics characteristics of JS019 are investigated. Four dosage groups are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg. The drug is administered intravenously every 3 weeks (Q3W). A treatment cycle is 21 days, with a DLT observation period of 21 days after the initial administration. The incremental dose and dosing interval may be adjusted as necessary during the study based on safety, PK, and other results obtained
Monotherapy Dose Expansion Stage:
According to RP2D of JS019 single drug dose, 3-5 specific tumor types are selected for indication expansion, and about 8-12 patients are enrolled for each indication. Tumor types and additional cases could be selected according to the specific situation in the trial process. It is planned to expand the cohort of lung cancer, pancreatic cancer, sarcoma, hepatocellular carcinoma, cholangiocarcinoma and other solid tumors to explore the efficacy and safety of JS019 single drug. The specific cohort will be adjusted according to the results of previous studies.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yilong Wu, bachelor's degree
- Phone Number: 86020-83877855
- Email: syylwu@live.cn
Study Contact Backup
- Name: Huajun Chen, Doctor of Medicine
- Phone Number: 8613710581145
- Email: chenhuajun@gdph.org.cn
Study Locations
-
-
Guangzhou
-
Guangdong, Guangzhou, China, 510062
- Recruiting
- Guangdong General Hospital
-
Contact:
- Yilong Wu, bachelor's degree
- Phone Number: 86020-83877855
- Email: syylwu@live.cn
-
Principal Investigator:
- Huajun Chen, Doctor of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be able to understand and willing to sign the Informed Consent Form;
- Male or female aged 18~75 years (included);
- Patients with pathologically confirmed advanced malignant solid tumors
- Failed or unsuitable for standard treatment;
- Eastern Cooperative Oncology Group (ECOG) physical fitness score: 0~1;
- Expected survival period ≥ 12 weeks;
- At least one measurable lesion according to criteria RECIST v1.1 ;
Exclusion Criteria:
- Patients with known hypersensitivity to the components of JS019;
- Patients who have received the treatment with anti-CD39 antibodies or inhibitors;
- Patients who participated in other clinical studies within 4 weeks prior to the first administration of JS019, except patients are in the follow-up period of observational (non-interventional) clinical study or interventional study;
- Patients who have received major surgery within 4 weeks before the first dose or expected to undergo major surgery during the study (as judged by the investigator) or are in the recovery period from surgery;
- Patients who have received anti-tumor therapy, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or biological therapy, within 4 weeks or 5 half-lives of the therapy (whichever is shorter) prior to the first dose of JS019. Patients who have received traditional Chinese medicine or Chinese patent medicine preparations with anti-tumor indications within 2 weeks before the first dose of JS019. Can accept hormone therapy for non-tumor-related diseases (such as insulin therapy for diabetes and hormone replacement therapy, etc.);
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation: dose level:0.3mg/kg
Dose Escalation: 0.3mg/kg, IV infusion, every 3 weeks (q3w).
|
Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W).
A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
|
Experimental: Dose Escalation: dose level:1 mg/kg
Dose Escalation: 1 mg/kg IV infusion, every 3 weeks (q3w).
|
Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W).
A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
|
Experimental: Dose Escalation: dose level:3 mg/kg
Dose Escalation: 3 mg/kg IV infusion, every 3 weeks (q3w).
|
Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W).
A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
|
Experimental: Dose Escalation: dose level:10 mg/kg
Dose Escalation: 10 mg/kg IV infusion, every 3 weeks (q3w).
|
Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W).
A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Incidence of DLT severity of adverse events (AEs) and serious adverse events (SAEs)and tolerability
Time Frame: 2 years
|
Incidence of DLT, incidence and severity of adverse events (AE) and severe adverse events (SAE), clinically significant abnormal laboratory changes and other tests
|
2 years
|
Maximum Tolerated Dose (MTD) or Optimal Biological Effect Dose (OBD) and Phase II study recommended dose (RP2D)
Time Frame: 2 years
|
The safety, pharmacokinetic and preliminary efficacy data of the comprehensive dose escalation were determined.
When MTD/OBD is determined, MTD/OBD is usually used as RP2D.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK)
Time Frame: 2 years
|
Drug concentrations in individual subjects at different time points after administration
|
2 years
|
Immunogenicity
Time Frame: 2 years
|
Incidence of anti-drug antibodies (ADA), titer of ADA-positive samples.
|
2 years
|
Pharmacodynamics (PD)
Time Frame: 2 years
|
CD39 receptor occupancy in peripheral blood.
|
2 years
|
Objective response rate (ORR)
Time Frame: 2 years
|
The percentage of cases with remission (PR + CR) after treatment was assessable
|
2 years
|
Duration of response (DOR)
Time Frame: 2 years
|
The time from the first assessment of CR or PR to the first assessment of PD or death due to any cause.
|
2 years
|
Disease control rate (DCR)
Time Frame: 2 years
|
The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable.
|
2 years
|
Time to response (TTR)
Time Frame: 2 years
|
time from the start of treatment to progression of diease.
|
2 years
|
Progression-free survival (PFS)
Time Frame: 2 years
|
PFS is defined as time from the start of treatment to progression of disease or death.
|
2 years
|
Overall survival (OS)
Time Frame: 2 years
|
Overall survival is defined as time from the start of treatment until death due to any reason.
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS019-002-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on JS019
-
Suzhou Kebo Ruijun Biotechnology Co., LtdRecruitingAdvanced Solid Tumors or LymphomasChina